NorthView Acquisition Corp - Tradeable Rights - Aug 2027
NVACR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$13.27K
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $13,271.00 |
|---|---|
| Enterprise Value | $12.70 Million |
| Earnings per Share | $-107.01 |
| Beta | 0.02 |
| Outstanding Shares | 57,676 |
Return
| Return on Equity | 142.73% |
|---|---|
| Return on Assets | -3715.66% |
| Return on Invested Capital | 120.58% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | -0.05 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.39 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.06 |
| Debt to Equity | -0.49 |
Revenue Sources
No data
Institutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 30.40%▲ 3.65% |
|---|---|
| Total Invested | $38,000▲ 31.03% |
| Investors Holding | 10% |
About Profusa, Inc. Common Stock
2 employees
CEO: Ben Chung-Bin Hwang
A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia